Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07430488
Recruiting Not applicable

Effect of Reading a Personal Narrative Book on Emotional Regulation in Women of Childbearing Age Undergoing Hysterectomy (RELIEF)

NCT07430488 · tracked via the Priya Life Science France tracker
Sponsor
Groupe SantéCité SantéCité Enseignement-Recherche-Innovation (GCS SCERI)
Phase
Not applicable
Started
2026-05-13
Last updated
2026-09-09

Condition(s) studied

HysterectomyAnxietyDepressionCatastrophizing

Investigational drug(s) / intervention(s)

personal narrative book

personal narrative book: Reading a personal narrative book written by a patient who underwent a hysterectomy

Study summary

The goal of this interventional clinical trial involving minimal risks and constraints is to evaluate whether an innovative approach to managing catastrophizing in the preoperative context of hysterectomy improves psychological outcomes compared to usual care in women of childbearing age who have been informed of an indication for hysterectomy.

The main questions it aims to answer are:

* Does the use of a personal narrative book improve adaptive emotional regulation and reduce catastrophizing, anxiety, and depressive symptoms in the preoperative period?
* Does this intervention improve postoperative patient satisfaction and reduce the need for additional supportive measures?

Researchers will compare standard care (CNGOF information leaflet with psychological consultation if needed) with an intervention including a personal narrative book in addition to standard care, to see if the intervention improves emotional regulation, psychological well-being, and satisfaction.

Participants will:

* provide explicit oral informed consent;
* complete questionnaires on their emotional and psychological experience;
* read a personal narrative book if they are randomized to the intervention group.

Eligibility

Sex
FEMALE
Min age
18 Years
Max age
42 Years
Healthy volunteers
No
Inclusion Criteria: * Women aged 18 years or older and under 43 years of age * Patients with an indication for hysterectomy for a non-malignant condition * Patients who have provided explicit oral consent to participate * Patients covered by the French social security system * Patients able to read and understand French and capable of reading a French book within a timeframe compatible with the study schedule Exclusion Criteria: * Women with suspected uterine cancer or high-grade dysplasia * Women participating or having participated to an interventional clinical trial within the 30 days prior to inclusion * Pregnant, breastfeeding, or parturient women * Protected patient: adults under guardianship or other legal protection; persons deprived of liberty by judicial or administrative order; persons hospitalized without consent * Patients with insufficient proficiency in the French language

Primary outcome measure(s)

Trial sites (4)

FacilityCityRegionStatus
Clinique Tivoli-Ducos Bordeaux France Recruiting
Clinique Charcot Sainte-Foy-lès-Lyon France Recruiting
Clinique Pasteur Toulouse Toulouse France Recruiting
Clinique St Cyprien Rive Gauche Toulouse France Recruiting

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07430488 on ClinicalTrials.gov ↗ ← All trials in France